Perspective: A Modern Progressive Approval System for Rare Diseases

Posted 16 April 2012 By Marc Dunoyer

The recent dramatic increase in the number of orphan drug designations has prompted patient groups, pharmaceutical companies, legislators and many other stakeholders to look for ways to accelerate the delivery of innovative new medicines to people with rare diseases. In particular, patients suffering from illnesses for which there are no adequate licensed therapies want access to promising new products earlier in the drug development cycle.

Share this article:

Tags: Orphan Diseases, Perspective, pharmaceutical, rare, Orphan, Rare Diseases, development, drug, disease

Regulatory Exchange: Latest Updates From the Community